BR112020018566A8 - Vacinas autólogas contra o câncer - Google Patents
Vacinas autólogas contra o câncerInfo
- Publication number
- BR112020018566A8 BR112020018566A8 BR112020018566A BR112020018566A BR112020018566A8 BR 112020018566 A8 BR112020018566 A8 BR 112020018566A8 BR 112020018566 A BR112020018566 A BR 112020018566A BR 112020018566 A BR112020018566 A BR 112020018566A BR 112020018566 A8 BR112020018566 A8 BR 112020018566A8
- Authority
- BR
- Brazil
- Prior art keywords
- vaccines against
- against cancer
- autologous
- cancer
- autologous vaccines
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 229940037642 autologous vaccine Drugs 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000001506 calcium phosphate Substances 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract 1
- 229940078499 tricalcium phosphate Drugs 0.000 abstract 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 abstract 1
- 235000019731 tricalcium phosphate Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B25/00—Phosphorus; Compounds thereof
- C01B25/16—Oxyacids of phosphorus; Salts thereof
- C01B25/26—Phosphates
- C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
VACINAS AUTÓLOGAS CONTRA O CÂNCER . A invenção refere-se a uma vacina autóloga contra o câncer e também ao método para produção da mesma compreendendo as seguintes etapas: a) extrair as proteínas contidas em uma amostra de soro ou plasma obtida de um paciente que sofre de câncer; e b) trazer as proteínas extraídas na etapa a) em contato com partículas de hidroxiapatita e/ou fosfato tricálcico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1852197 | 2018-03-14 | ||
| FR1852197A FR3078887B1 (fr) | 2018-03-14 | 2018-03-14 | Vaccins autologues contre le cancer |
| PCT/FR2019/050537 WO2019175500A1 (fr) | 2018-03-14 | 2019-03-13 | Vaccins autologues contre le cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112020018566A2 BR112020018566A2 (pt) | 2020-12-29 |
| BR112020018566A8 true BR112020018566A8 (pt) | 2022-09-13 |
Family
ID=62873447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020018566A BR112020018566A8 (pt) | 2018-03-14 | 2019-03-13 | Vacinas autólogas contra o câncer |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11839648B2 (pt) |
| EP (1) | EP3765067A1 (pt) |
| JP (2) | JP2021515790A (pt) |
| AR (1) | AR114696A1 (pt) |
| AU (1) | AU2019235488A1 (pt) |
| BR (1) | BR112020018566A8 (pt) |
| CA (1) | CA3093576A1 (pt) |
| FR (1) | FR3078887B1 (pt) |
| WO (1) | WO2019175500A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4124663A1 (en) | 2021-07-29 | 2023-02-01 | Hastim | Methods for predicting a response to cancer treatment |
| WO2023114273A1 (en) * | 2021-12-14 | 2023-06-22 | Lurong Zhang | Methods of treating cancer and monitoring anti-cancer immunity |
| US20230398145A1 (en) * | 2022-06-09 | 2023-12-14 | Ravi PONNAPPAN | Method of inducing an immune response |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0673470B2 (ja) * | 1986-07-15 | 1994-09-21 | 協和醗酵工業株式会社 | 抗ヒト胃癌単クロ−ン性抗体ａｍｃ−４６２ |
| JPS6341427A (ja) * | 1986-08-08 | 1988-02-22 | Wakunaga Pharmaceut Co Ltd | ヒト癌抗原 |
| US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
| US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
| JP4569946B2 (ja) * | 2003-10-21 | 2010-10-27 | セルメディシン株式会社 | リン酸カルシウム微粒子 |
| FR2885525B1 (fr) * | 2005-05-13 | 2009-09-18 | Urodelia Sa | Medicament notamment anti-cancereux, destine a des traitements par immunotherapie, en particulier autologue |
| WO2011135393A1 (es) * | 2010-04-27 | 2011-11-03 | Universidad Manuela Beltran | Vacuna biologica autologa contra el cancer |
| FR3005649B1 (fr) * | 2013-05-15 | 2023-03-31 | Urodelia | Poudre d'hydroxyapatite et son procede de production, composition a base de cette poudre et son procede de preparation et kit comprenant cette poudre |
| WO2018047797A1 (ja) * | 2016-09-06 | 2018-03-15 | セルメディシン株式会社 | 免疫刺激剤 |
-
2018
- 2018-03-14 FR FR1852197A patent/FR3078887B1/fr active Active
-
2019
- 2019-03-13 US US16/979,970 patent/US11839648B2/en active Active
- 2019-03-13 JP JP2020548756A patent/JP2021515790A/ja active Pending
- 2019-03-13 BR BR112020018566A patent/BR112020018566A8/pt unknown
- 2019-03-13 CA CA3093576A patent/CA3093576A1/fr active Pending
- 2019-03-13 WO PCT/FR2019/050537 patent/WO2019175500A1/fr unknown
- 2019-03-13 AU AU2019235488A patent/AU2019235488A1/en active Pending
- 2019-03-13 AR ARP190100626A patent/AR114696A1/es unknown
- 2019-03-13 EP EP19713118.8A patent/EP3765067A1/fr active Pending
-
2023
- 2023-11-03 US US18/386,742 patent/US20240148846A1/en active Pending
- 2023-12-07 JP JP2023206639A patent/JP2024028888A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210008187A1 (en) | 2021-01-14 |
| US20240148846A1 (en) | 2024-05-09 |
| JP2021515790A (ja) | 2021-06-24 |
| EP3765067A1 (fr) | 2021-01-20 |
| WO2019175500A1 (fr) | 2019-09-19 |
| FR3078887A1 (fr) | 2019-09-20 |
| FR3078887B1 (fr) | 2020-12-18 |
| AU2019235488A1 (en) | 2020-10-15 |
| JP2024028888A (ja) | 2024-03-05 |
| CA3093576A1 (fr) | 2019-09-19 |
| US11839648B2 (en) | 2023-12-12 |
| AR114696A1 (es) | 2020-10-07 |
| BR112020018566A2 (pt) | 2020-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020018566A8 (pt) | Vacinas autólogas contra o câncer | |
| BR112017001420A2 (pt) | método | |
| MX2020004948A (es) | Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación. | |
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| BR112017020893A2 (pt) | método para o tratamento de câncer | |
| BR112019003785A2 (pt) | tabaco resistente a vírus e método de melhoramento para o mesmo | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| BR112017023391A2 (pt) | ?composição, método para preparar uma composição e métodos para melhorar a hidratação da pele? | |
| EA201892663A1 (ru) | Аналоги фосфолипидного эфира для идентификации и выделения циркулирующих опухолевых клеток | |
| BR112019027133B8 (pt) | Uso de uma célula imune modificada deficiente para suv39h1 | |
| JOP20220030A1 (ar) | صيغ مضادة لـ c5 عالية التركيز | |
| BR112018076234A2 (pt) | vacina contra o vírus da bronquite infecciosa | |
| BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
| BR112018008840A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
| BR112016006383A2 (pt) | método de extração de proteína | |
| BR112018009618A2 (pt) | processo para fabricação de uma dispersão aquosa compreendendo farelo de mostarda, emulsão de óleo em água e processo de fabricação de uma emulsão de óleo em água | |
| CO2021003136A2 (es) | Terapias de combinación | |
| BR112021026506A2 (pt) | Método para fabricar anamicina liofilizada, método para produzir liofilizado de anamicina pré-lipossômico, composição de liofilizado de anamicina pré-lipossômico e método para tratar câncer | |
| BR112018007551A2 (pt) | método para detectar anticorpos neutralizantes contra insulina humana recombinante em soro humano | |
| BR112015023968A2 (pt) | Uso de um veículo de levedura e um antígeno do câncer compreendendo pelo menos um antígeno de brachyury na preparação de uma composição imunoterapêutica para tratar ou prevenir cordoma, bem como composição assim preparada | |
| BR112022021797A2 (pt) | Proteínas de fusão para imunoterapia contra o câncer e doenças infecciosas | |
| BR112017022656A2 (pt) | conservação in vitro de células terapêuticas | |
| AR104371A1 (es) | Procedimiento para la preparación de una composición que comprende fibras proteicas | |
| BR112012020089A2 (pt) | formulações de retinol e métodos para utilização das mesmas | |
| BR112021022293A2 (pt) | Composições de oligossacarídeos e métodos de uso das mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: URODELIA (FR) |
|
| B25D | Requested change of name of applicant approved |
Owner name: HASTIM (FR) |